North China Pharmaceutical Co Ltd (600812):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:North China Pharmaceutical Co Ltd (600812) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8073
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:19
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
North China Pharmaceutical Co Ltd (NCPC), a subsidiary of North China Pharmaceutical Group Corp is a pharmaceutical company that develops, produces and sells novel drugs and pharmaceutical related products. The company offers preparation products, nutrition, pharmaceutical raw materials and intermediates, pesticide and veterinary products, among others. It offers products in the dosage forms of granules, capsules, and tablets. NCPC offers integration and management services. The company sells its products in through a network of distributors in China and abroad. NCPC is headquartered in Shijiazhuang, Hebei, China.

North China Pharmaceutical Co Ltd (600812) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
North China Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
North China Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
North China Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
North China Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 8
North China Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 9
Equity Offering 9
North China Pharma Receives Approval From China Securities Regulatory Commission For Private Placement Of Shares For US$183.4 Million 9
North China Pharma Completes Private Placement Of Shares For US$471 Million 10
Debt Offering 11
North China Pharma to Raise USD44 Million in Private Placement of Bonds Due 2021 11
North China Pharma to Raise up to USD74 Million in Private Placement of Bonds Due 2021 12
North China Pharma Raises USD147 Million in Public Offering of 5.3% Bonds Due 2018 13
North China Pharmaceutical Plans to Raise USD108.2 Million in Public Offering of Bonds Due 2021 14
North China Pharma Announces Public Offering Of Notes For US$73 Million 15
Acquisition 16
North China Pharma To Acquire Remaining 50% Stake In Pharmaceutical Company For US$14.2 Million 16
North China Pharmaceutical Co Ltd – Key Competitors 17
North China Pharmaceutical Co Ltd – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Appendix 19
Methodology 19
About GlobalData 19
Contact Us 19
Disclaimer 19

List of Tables
North China Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
North China Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 2
North China Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
North China Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
North China Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
North China Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 8
North China Pharma Receives Approval From China Securities Regulatory Commission For Private Placement Of Shares For US$183.4 Million 9
North China Pharma Completes Private Placement Of Shares For US$471 Million 10
North China Pharma to Raise USD44 Million in Private Placement of Bonds Due 2021 11
North China Pharma to Raise up to USD74 Million in Private Placement of Bonds Due 2021 12
North China Pharma Raises USD147 Million in Public Offering of 5.3% Bonds Due 2018 13
North China Pharmaceutical Plans to Raise USD108.2 Million in Public Offering of Bonds Due 2021 14
North China Pharma Announces Public Offering Of Notes For US$73 Million 15
North China Pharma To Acquire Remaining 50% Stake In Pharmaceutical Company For US$14.2 Million 16
North China Pharmaceutical Co Ltd, Key Competitors 17
North China Pharmaceutical Co Ltd, Other Locations 18
North China Pharmaceutical Co Ltd, Subsidiaries 18

List of Figures
North China Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
North China Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
North China Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
North China Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
North China Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
North China Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

★海外企業調査レポート[North China Pharmaceutical Co Ltd (600812):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • The Mosaic Company:企業の戦略・SWOT・財務分析
    The Mosaic Company - Strategy, SWOT and Corporate Finance Report Summary The Mosaic Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Murphy Oil Corp Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Murphy Oil Corp Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Murphy Oil Corp (Murphy) is an international independent oil and gas exploration and production company. It explores for and produces crude oil, natural gas, and natural gas liquids. The company oper …
  • Pt Indofood Sukses Makmur Tbk:企業の戦略・SWOT・財務分析
    Pt Indofood Sukses Makmur Tbk - Strategy, SWOT and Corporate Finance Report Summary Pt Indofood Sukses Makmur Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Ingersoll-Rand plc:企業の戦略・SWOT・財務情報
    Ingersoll-Rand plc - Strategy, SWOT and Corporate Finance Report Summary Ingersoll-Rand plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Zeus Co., Ltd. (079370):企業の財務・戦略的SWOT分析
    Zeus Co., Ltd. (079370) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • S Chand And Company Limited (SCHAND):企業の財務・戦略的SWOT分析
    S Chand And Company Limited (SCHAND) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Quantum Pharma Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Quantum Pharma Ltd (Quantum Pharma), a subsidiary Clinigen Group Plc, is a manufacturer and supplier of unlicensed medicines. The company develops, manufactures, and supplies niche pharmaceutical products. It offers dermatology products, branded generics and vitamins, borderline substances, …
  • Vitruvian Exploration II LLC:石油・ガス:M&Aディール及び事業提携情報
    Summary Vitruvian Exploration II LLC (Vitruvian Exploration II) is an oil and gas company that provides exploration and development of oil properties. The company provides exploration of onshore North American unconventional oil and gas resource plays. Its VEX II Woodford Apollo project has various …
  • GOBARTO S.A.:企業の戦略・SWOT・財務分析
    GOBARTO S.A. - Strategy, SWOT and Corporate Finance Report Summary GOBARTO S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • CST Brands, Inc. (CST)-石油・ガス分野:企業M&A・提携分析
    Summary CST Brands, Inc. (CST) is a holding company,primarily involved in wholesaling and retailing motor fuels and convenience goods in North America. The company operates retail sites under Corner Store, Dépanneur du Coin banners, Flash Foods,Landmark, and Nice N Easy. Apart from motor fuel, these …
  • Bristol-Myers Squibb Co (BMY)-製薬・医療分野:企業M&A・提携分析
    Summary Bristol-Myers Squibb Company (BMS) is specialty biopharmaceutical company that carries out the discovery, development, licensing, manufacturing, marketing, distribution and sale of medicines to patients with serious diseases. Its primary focus is in cancer, cardiovascular, immunoscience and …
  • International Business Machines Corp (IBM):企業の財務・戦略的SWOT分析
    International Business Machines Corp (IBM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengt …
  • Kukje Pharmaceutical Industry Co Ltd (002720):企業の財務・戦略的SWOT分析
    Summary Kukje Pharmaceutical Industry Co Ltd (Kukje) is a manufacturer, and distributor of pharmaceuticals, cosmetics and healthcare products. The company’s products include cephalosporins, penicillins, quinolones, aminoglycosides, macrolides, other antibiotics, antifungal and antiviral agents. Kukj …
  • University of Michigan-製薬・医療分野:企業M&A・提携分析
    Summary University of Michigan (UM) is an educational service provider that offers educational and research services. The university offers graduate, undergraduate and post-doctoral levels programs in various disciplines. It operates various graduate schools and colleges of graduate studies, archite …
  • Krystal Biotech Inc (KRYS):製薬・医療:M&Aディール及び事業提携情報
    Summary Krystal Biotech Inc (Krystal Biotech) is a drug development company that uses gene therapy to develop novel treatments for skin diseases. The company’s pipeline products include KB103, KB105, and KB200. Its products are used for the treatment of dystrophic EB, TGM1-deficient autosomal recess …
  • ViroMed Co Ltd (084990):製薬・医療:M&Aディール及び事業提携情報
    Summary ViroMed Co Ltd (ViroMed), formerly ViroMedica Pacific Inc is a biotechnology company that discovers and develops biopharmaceuticals and phytotherapeutics for human diseases. The company provides therapeutic drugs such as therapeutic angiogenesis for cardiovascular diseases, therapeutic cance …
  • ACUTRONIC USA, Inc.:企業の戦略・SWOT・財務情報
    ACUTRONIC USA, Inc. - Strategy, SWOT and Corporate Finance Report Summary ACUTRONIC USA, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Turkiye Petrol Rafinerileri AS (TUPRS):石油・ガス:M&Aディール及び事業提携情報
    Summary Turkiye Petrol Rafinerileri AS (Tupras), a subsidiary of Enerji Yatirimlari AS, is a downstream energy company. It refines crude oil and marketing of petroleum products. The company operates refineries in Izmit, Izmir, Kirikkale and Batman, and is mainly active in Turkey. Tupras’s refineries …
  • NetSuite Inc.:企業の戦略的SWOT分析
    NetSuite Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • PG&E Corp:企業の発電所・SWOT分析2018
    PG&E Corp - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (executiv …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆